MedTrace Logo

Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI

NCT07457541 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-06-25

No results posted yet for this study

Summary

The study should evaluate the biological distribution of 99mTc-HYNIC-FAPI in metastatic cancer patients.

Conditions

  • Lung Cancer (Locally Advanced or Metastatic)
  • Pancreas Cancer, Metastatic
  • Breast Cancer (Locally Advanced or Metastatic)
  • Colorectal Cancer (Locally Advanced or Metastatic)

Interventions

DRUG

[99mTc]Tc-HYNIC-FAPI

One single intravenous injection of \[99mTc\]Tc-HYNIC-FAPI, followed by gamma camera imaging after 2, 4, 6 and 24 hours.

Sponsors & Collaborators

  • Tomsk National Research Medical Center of the Russian Academy of Sciences

    lead OTHER

Principal Investigators

  • Vladimir I Chernov, MD, Prof. · TomskNRMC Tomsk, Russia

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-26
Primary Completion
2026-12-31
Completion
2027-05-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07457541 on ClinicalTrials.gov